{
    "organizations": [],
    "uuid": "ae1e5b7fc62594b8b4f4076d47a45356232eb3c2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1PS1MM",
    "ord_in_thread": 0,
    "title": "BRIEF-Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 2 (Reuters) - Crossject SA:\n* ANNOUNCED ON THURSDAY THAT FDA ATTRIBUTED TO ZENEO MIDAZOLAM THE OPRHAN DRUG STATUS\n* CROSSJECT CONFIRMS THE OBJECTIVE OF RA SUBMISSION FOR ZENEO MIDAZOLAM IN 2019, IN THE USA AND IN EUROPE\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-02T15:57:00.000+02:00",
    "crawled": "2018-02-03T21:18:52.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "crossject",
        "sa",
        "announced",
        "thursday",
        "fda",
        "attributed",
        "zeneo",
        "midazolam",
        "oprhan",
        "drug",
        "status",
        "crossject",
        "confirms",
        "objective",
        "ra",
        "submission",
        "zeneo",
        "midazolam",
        "usa",
        "europe",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}